<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Pravastatin" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Pravastatin</book-part-id>
      <title-group>
        <title>Pravastatin</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>12</month>
          <year>2021</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Prasugrel" document-type="chapter">Prasugrel</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Praziquantel" document-type="chapter">Praziquantel</related-object>
    </book-part-meta>
    <body>
      <sec id="Pravastatin.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Pravastatin.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Pravastatin is a commonly used cholesterol lowering agent (statin) that is associated with mild, asymptomatic and self-limited serum aminotransferase elevations during therapy, and rarely with clinically apparent acute liver injury.</p>
        </sec>
        <sec id="Pravastatin.Background">
          <title>Background</title>
          <p>Pravastatin (pra" va stat' in) is an orally available inhibitor of hepatic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the major rate-limiting enzyme in cholesterol synthesis. Like other members of its class (the &#x0201c;statins&#x0201d;), pravastatin lowers total serum cholesterol and low densitylipoprotein (LDL) concentrations, thereby reducing the risk of atherosclerosis and its complications &#x02013; myocardial infarction and stroke. Pravastatin was approved for use in the United States in 1991 and continues to be widely used with more than 9 million prescriptions filled yearly. Current indications are for treatment of hypercholesterolemia in persons at high risk for coronary, cerebrovascular and peripheral artery disease. Pravastatin is available in tablets of 10, 20, 40 and 80 mg in several generic forms and under the brand name of Pravachol. The recommended dose in adults is 40 to 80 mg once daily. Common side effects include muscle cramps, joint aches, abdominal pain, nausea, headache and weakness, symptoms that occur with all of the currently available statins. Rare but potentially severe adverse events include liver injury, myopathy, rhabdomyolysis, and immune-mediated necrotizing myopathy.</p>
        </sec>
        <sec id="Pravastatin.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Pravastatin therapy is associated with mild, asymptomatic and usually transient serum aminotransferase elevations. In summary analyses of large scale studies with prospective monitoring, ALT elevations above normal occurred in 3% to 7% of patients; but levels above 3 times the upper limit of normal (ULN) occurred in less than 1.2% of both pravastatin- as well as in placebo-treated subjects. Most of these elevations were self-limited and did not require dose modification. Pravastatin has been only rarely associated with clinically apparent hepatic injury with symptoms or jaundice at a rate estimated to be 1 per 100,000 users or less. In the case reports, latency varied from 2 to 9 months and the pattern of serum enzyme elevations from cholestatic to hepatocellular. Recovery was complete within a few months. Rash, fever and eosinophilia were uncommon as were autoantibodies, but few cases have been reported and the full clinical syndrome not well defined. Pravastatin appears to be less likely to cause clinically apparent liver injury than atorvastatin, simvastatin and rosuvastatin.</p>
          <p>Likelihood score: B (likely cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Pravastatin.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The cause of hepatic injury from pravastatin is unknown. Pravastatin has only minimal hepatic metabolism and most is excreted unchanged in the urine. The mild, self-limited ALT elevations may be due to production of a minor toxic intermediate of metabolism and the reversal of these elevations due to adaptation. The idiosyncratic, clinically apparent liver injury associated with pravastatin may be due to immune mediated responses.</p>
        </sec>
        <sec id="Pravastatin.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>The product labels for most statins recommend screening for liver test abnormalities before starting therapy and repeating tests as clinically indicated. The mild ALT elevations associated with pravastatin therapy are usually self-limited and do not require dose modification, although pravastatin should be stopped if ALT levels rise above 10-fold the ULN, or persist in being above 5-fold elevated or are associated with symptoms. In the clinically apparent liver injury attributed to pravastatin, recovery was usually complete within 1 to 2 months. In view of the wide scale use of pravastatin, clinically apparent and severe liver injury is extraordinarily rare. Recurrence of injury with rechallenge has been reported and should be avoided. Switching therapy to another statin after pravastatin induced injury can lead to recurrence and should be done with careful monitoring.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="Lipid-LoweringAgents" document-type="chapter">Antilipemic Agents</related-object></p>
          <p>Other Drugs in the Subclass, <related-object link-type="booklink" source-id="livertox" document-id="Statins" document-type="chapter">Statins</related-object>: <related-object link-type="booklink" source-id="livertox" document-id="Atorvastatin" document-type="chapter">Atorvastatin</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Ezetimibe" document-type="chapter">Ezetimibe [used in combination]</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Fluvastatin" document-type="chapter">Fluvastatin</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Lovastatin" document-type="chapter">Lovastatin</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Pitavastatin" document-type="chapter">Pitavastatin</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Rosuvastatin" document-type="chapter">Rosuvastatin</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Simvastatin" document-type="chapter">Simvastatin</related-object></p>
        </sec>
      </sec>
      <sec id="Pravastatin.CASE_REPORT">
        <title>CASE REPORT</title>
        <sec id="Pravastatin.Case_1_Acute_cholestatic_hep">
          <title>Case 1. Acute cholestatic hepatitis attributed to pravastatin therapy.(<xref ref-type="bibr" rid="Pravastatin.REF.1">1</xref>)</title>
          <p>A 57 year old man developed abdominal pain and nausea followed by fever and jaundice 6 weeks after starting pravastatin (20 mg daily) for long standing hypercholesterolemia. He had a history of coronary artery disease and had been treated with beta blockers and various cholesterol lowering drugs, including fenofibrate and simvastatin in the past. At the time of presentation, he was taking only pravastatin and metoprolol, both of which were discontinued promptly. He denied alcohol use and had no risk factors for viral hepatitis. Physical examination showed jaundice and hepatic tenderness but no rash, fever, or signs of chronic liver disease. Laboratory results showed a cholestatic pattern of serum enzyme elevations and hyperbilirubinemia (Table). Tests for hepatitis A, B and C were negative as were autoantibodies. Ultrasound and CT of the abdomen showed no evidence of biliary obstruction and ERCP was normal. A liver biopsy showed intrahepatic cholestasis compatible with drug induced liver injury. He was treated with ursodiol (750 mg daily). Once pravastatin was stopped, symptoms and liver test abnormalities improved rapidly and were completely normal 7 weeks later.</p>
          <sec id="Pravastatin.Key_Points">
            <title>Key Points</title>
            <table-wrap id="Pravastatin.Tc" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Pravastatin.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Pravastatin.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">Pravastatin (20 mg daily)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Pravastatin.Tc_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Pravastatin.Tc_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Mixed (R=2.8)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Pravastatin.Tc_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Pravastatin.Tc_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">3+ (jaundice, hospitalization)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Pravastatin.Tc_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Pravastatin.Tc_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">6 weeks</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Pravastatin.Tc_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Pravastatin.Tc_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">~7 weeks</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Pravastatin.Tc_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Pravastatin.Tc_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">Metoprolol</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Pravastatin.Laboratory_Values">
            <title>Laboratory Values</title>
            <table-wrap id="Pravastatin.Td" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Pravastatin.Td_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Pravastatin.Td_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Stopping</th>
                    <th id="hd_h_Pravastatin.Td_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">ALT*<break/>(U/L)</th>
                    <th id="hd_h_Pravastatin.Td_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">Alk P*<break/>(U/L)</th>
                    <th id="hd_h_Pravastatin.Td_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">Bilirubin<break/>(mg/dL)</th>
                    <th id="hd_h_Pravastatin.Td_1_1_1_6" valign="top" align="center" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">6 weeks</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">421</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">482</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">13.6</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Admission</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2 days</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">260</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">11.8</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">8 weeks</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2 weeks</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">151</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">3.7</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">9 weeks</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">3 weeks</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">255</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">3.0</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Liver biopsy</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">10 weeks</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">4 weeks</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">210</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">1.9</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Discharge</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">3 months</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">7 weeks</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">40</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">0.5</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Outpatient follow up</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_1 hd_h_Pravastatin.Td_1_1_1_2" colspan="2" valign="top" align="center" scope="row" rowspan="1">
<bold>Normal Values</bold>
</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;40</bold>
</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;130</bold>
</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">
<bold>&#x0003c;1.2</bold>
</td>
                    <td headers="hd_h_Pravastatin.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="Pravastatin.TF.d.1">
                  <label>* </label>
                  <p>Some values estimated from Figure 1.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
          <sec id="Pravastatin.Comment">
            <title>Comment</title>
            <p>The onset of injury within 2 months of starting pravastatin and resolution within 2 months of stopping is supportive evidence that this represented drug induced liver disease due to pravastatin. All other causes of acute liver injury were satisfactorily excluded. Metoprolol had been used for a longer period and, like other beta-blockers, is a rare cause of drug induced liver injury. The pattern of serum enzyme elevations was considered &#x0201c;mixed&#x0201d; but the clinical presentation, symptoms and liver histology were more cholestatic. This patient had previously tolerated simvastatin without obvious liver injury. Cross susceptibility to cholestatic hepatitis from the statins is frequent but not invariable.</p>
          </sec>
        </sec>
      </sec>
      <sec id="Pravastatin.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Pravastatin &#x02013; Generic, Pravachol&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Antilipemic Agents</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=pravastatin">COMPLETE LABELING</ext-link>
</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Pravastatin.CHEMICAL_FORMULA_AND_STRUCTU">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Pravastatin.Te" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Pravastatin.Te_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Pravastatin.Te_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Pravastatin.Te_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Pravastatin.Te_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Pravastatin.Te_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pravastatin</td>
                <td headers="hd_h_Pravastatin.Te_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135014686">81093-37-0</ext-link>
</td>
                <td headers="hd_h_Pravastatin.Te_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C23-H36-O7</td>
                <td headers="hd_h_Pravastatin.Te_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
<related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135014686" document-id-type="sid" document-type="summary" object-id="135014686" object-id-type="sid" object-type="image"/>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Pravastatin.CITED_REFERENCE">
        <title>CITED REFERENCE</title>
        <ref-list id="Pravastatin.CITED_REFERENCE.reflist0">
          <ref id="Pravastatin.REF.1">
            <label>1</label>
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Hartleb</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Rymarczyk</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Januszewski</surname><given-names>K</given-names></name>
</person-group>
              <article-title>Acute cholestatic hepatitis associated with pravastatin.</article-title>
              <source>Am J Gastroenterol</source>
              <year>1999</year>
              <volume>94</volume>
              <fpage>1388</fpage>
              <lpage>90</lpage>
              <pub-id pub-id-type="pmid">10235223</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec id="Pravastatin.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 01 December 2021</p>
        <p>Abbreviations used: ANA, antinuclear antibody; HDL, high density lipoprotein; LDL, low density lipoprotein; OD, odds ratio.</p>
        <ref-list id="Pravastatin.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Pravastatin.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Drugs used in the treatment of hypercholesterolemia and hyperlipidemia. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 660-2.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999; the statins have dose related hepatic effects in guinea pigs and rabbits and transient elevations in aminotransferases occur in 1-5% of humans treated; several cases of clinically apparent liver injury from lovastatin and simvastatin have been published).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Pravastatin.REF.de_marzio.2013">
            <mixed-citation publication-type="book">De Marzio DH, Navarro VJ. Hepatotoxicity of cardiovascular and antidiabetic medications. Lipid lowering agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 519-40.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of lipid lowering agents; asymptomatic elevations in aminotransferases are common in patients receiving statins, but clinically significant hepatotoxicity is rare).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Pravastatin.REF.gurgle.2018">
            <mixed-citation publication-type="book">Gurgle H, Blumenthal DK. Drug therapy for dyslipidemias. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 605-618.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics; &#x0201c;Serious hepatotoxicity is rare and unpredictable, with a rate of about 1 case per million person-years of use.&#x0201d; Multiple academic societies and the FDA recommend testing all patients for routine liver tests before starting statins but monitoring or retesting only if symptoms arise).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Pravastatin.REF.ballar_.1992.41">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Ballar&#x000e8;</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Campanini</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Airoldi</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Zaccala</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Bertoncelli</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Cornaglia</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Porzio</surname><given-names>M</given-names></name>
<etal/>
</person-group>
              <article-title>Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors.</article-title>
              <source>Minerva Gastroenterol Dietol</source>
              <year>1992</year>
              <volume>38</volume>
              <fpage>41</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective monitoring identified ALT elevations in 5% of 100 patients on simvastatin and 4.5% of 90 on pravastatin).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">1520752</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.the_lovastatin_pravastatin_study_group.1993.810">
            <element-citation publication-type="journal">
              <person-group>
<collab>The Lovastatin Pravastatin Study Group</collab>
</person-group>
              <article-title>A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia.</article-title>
              <source>Am J Cardiol</source>
              <year>1993</year>
              <volume>71</volume>
              <fpage>810</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Controlled trial of lovastatin [20 to 80 mg] vs pravastatin [10 to 40 mg] daily for 18 weeks in 672 hypercholesterolemic patients; ALT elevations &#x0003e;3 times ULN occurred in 1 lovastatin and 2 pravastatin treated patients; no clinically apparent liver injury mentioned).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">8456759</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.morris.1996.319">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Morris</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Robinson</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Tilyard</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Gurr</surname><given-names>E</given-names></name>
</person-group>
              <article-title>Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia.</article-title>
              <source>NZ Med J</source>
              <year>1996</year>
              <volume>109</volume>
              <fpage>319</fpage>
              <lpage>22</lpage>
              <annotation>
                <p>
<italic toggle="yes">(In a prospective controlled trial in 78 patients, transient liver test abnormalities occurred in 3 patients on pravastatin [18%] and 7 [18%] on placebo; none led to discontinuation and none had symptoms or jaundice).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">8816723</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.hartleb.1999.1388">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Hartleb</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Rymarczyk</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Januszewski</surname><given-names>K</given-names></name>
</person-group>
              <article-title>Acute cholestatic hepatitis associated with pravastatin.</article-title>
              <source>Am J Gastroenterol</source>
              <year>1999</year>
              <volume>94</volume>
              <fpage>1388</fpage>
              <lpage>90</lpage>
              <annotation>
                <p>
<italic toggle="yes">(57 year old man developed jaundice, 2 months after starting pravastatin [bilirubin 13.6 mg/dL, ALT 421 U/L, Alk P 482 U/L], resolving within 8 weeks of stopping: Case 1).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">10235223</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.heuer.2000.642">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Heuer</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Gerards</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Pauw</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Gabbert</surname><given-names>HE</given-names></name>
<name name-style="western"><surname>Reis</surname><given-names>HE</given-names></name>
</person-group>
              <comment>[Toxic liver damage caused by HMG-CoA reductase inhibitor]</comment>
              <source>Med Klin (Munich)</source>
              <year>2000</year>
              <volume>95</volume>
              <fpage>642</fpage>
              <lpage>4</lpage>
              <comment>German.</comment>
              <annotation>
                <p>
<italic toggle="yes">(4 patients with liver injury due to statins: 3 simvastatin and 1 pravastatin with jaundice arising 8-24 months after starting [bilirubin 1.9 to 7.4 mg/dL, ALT 39 to 841 U/L, Alk P 266 to 353], resolving within 3 months of stopping).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">11143546</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.punthakee.2001.249">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Punthakee</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Scully</surname><given-names>LJ</given-names></name>
<name name-style="western"><surname>Guindi</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Ooi</surname><given-names>TC</given-names></name>
</person-group>
              <article-title>Liver fibrosis attributed to lipid lowering medications: two cases.</article-title>
              <source>J Intern Med</source>
              <year>2001</year>
              <volume>250</volume>
              <fpage>249</fpage>
              <lpage>54</lpage>
              <annotation>
                <p>
<italic toggle="yes">(39 year old man developed fever and weakness 9 months after starting pravastatin [ALT ~500 U/L, but no jaundice], resolving rapidly with stopping and then recurring after 22 months of simvastatin therapy [ALT ~2800 U/L, ANA negative], biopsy showing chronic hepatitis whereas his enzymes remained normal over the next 6 years on no-statin therapy).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">11555130</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.hartleb.2002.cr292">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Hartleb</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Biernat</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Kochel</surname><given-names>A.</given-names></name>
</person-group>
              <article-title>Drug-induced liver damage--a three-year study of patients from one gastroenterological department.</article-title>
              <source>Med Sci Monit</source>
              <year>2002</year>
              <volume>8</volume>
              <fpage>CR292</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
<italic toggle="yes">(14 patients with drug induced liver injury seen in one hospital [Silesian Medical University] over 3 year period; due to amoxicillin/clavulanate in 3, antituberculosis agents 2, pravastatin 2, fluvastatin 1, and 6 other agents in 1 each; 2 pravastatin cases in 62 and 57 year olds with onset after 4 and 7 weeks [bilirubin 1.0 and 13.6 mg/dL, ALT 3.4 and 10.5 times ULN, Alk P 1.0 and 4.4 times ULN], one case with rapid recovery upon stopping and the other [with jaundice] protracted).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">11951073</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.batey.2002.561">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Batey</surname><given-names>RG</given-names></name>
<name name-style="western"><surname>Harvey</surname><given-names>M</given-names></name>
</person-group>
              <article-title>Cholestasis associated with the use of pravastatin sodium.</article-title>
              <source>Med J Aust</source>
              <year>2002</year>
              <volume>176</volume>
              <fpage>561</fpage>
              <annotation>
                <p>
<italic toggle="yes">(64 year old woman developed abnormal liver tests 4 months after starting pravastatin [bilirubin 0.8 mg/dL, ALT 85 U/L, Alk P 362 U/L], improving on stopping and rising again with restarting, decreasing upon stopping but not to normal; never jaundiced or symptomatic).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">12064992</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.pfeffer.2002.2341">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Pfeffer</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Keech</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Sacks</surname><given-names>FM</given-names></name>
<name name-style="western"><surname>Cobbe</surname><given-names>SM</given-names></name>
<name name-style="western"><surname>Tonkin</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Byington</surname><given-names>RP</given-names></name>
<name name-style="western"><surname>Davis</surname><given-names>BR</given-names></name>
<etal/>
</person-group>
              <article-title>Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project.</article-title>
              <source>Circulation</source>
              <year>2002</year>
              <volume>105</volume>
              <fpage>2341</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Controlled trial of pravastatin vs placebo for 5 years in ~18,000 patients with hypercholesterolemia; no differences in rates of adverse events, gallstones in 1.9% vs 2.1% [pravastatin vs placebo], any abnormal ALT in 8.8% vs 8.2% and ALT &#x0003e;3 times ULN in 1.4% vs 1.3%).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">12021218</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.rosenson.2003.878">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Rosenson</surname><given-names>RS</given-names></name>
<name name-style="western"><surname>Bays</surname><given-names>HE</given-names></name>
</person-group>
              <article-title>Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day.</article-title>
              <source>Am J Cardiol</source>
              <year>2003</year>
              <volume>91</volume>
              <fpage>878</fpage>
              <lpage>81</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Two placebo controlled trials of higher doses of pravastatin [40 and 160 mg/day for 6 weeks]; no ALT or AST elevations above 3 times the ULN in either study).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">12667578</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.parra.2003.415">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Parra</surname><given-names>JL</given-names></name>
<name name-style="western"><surname>Reddy</surname><given-names>KR</given-names></name>
</person-group>
              <article-title>Hepatotoxicity of hypolipidemic drugs.</article-title>
              <source>Clin Liver Dis</source>
              <year>2003</year>
              <volume>7</volume>
              <fpage>415</fpage>
              <lpage>33</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review and discussion of individual agents; rate of serum ALT elevations with pravastatin has been similar to that with placebo; mentions that single case report of cholestatic hepatitis due to pravastatin has appeared in the literature).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">12879992</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.de_denus.2004.584">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>de Denus</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Spinler</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>Miller</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Peterson</surname><given-names>AM</given-names></name>
</person-group>
              <article-title>Statins and liver toxicity: a meta-analysis.</article-title>
              <source>Pharmacotherapy</source>
              <year>2004</year>
              <volume>24</volume>
              <fpage>584</fpage>
              <lpage>91</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Systematic review of 13 large controlled trials of statins with at least 48 weeks of therapy in 43,390 patients; overall odds ratio for liver test abnormalities with statins versus placebo was 1.26; lovastatin 1.78; simvastatin 1.06; pravastatin 1.00, and fluvastatin, 3.54).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15162892</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.rallidis.2004.193">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Rallidis</surname><given-names>LS</given-names></name>
<name name-style="western"><surname>Drakoulis</surname><given-names>CK</given-names></name>
<name name-style="western"><surname>Parasi</surname><given-names>AS</given-names></name>
</person-group>
              <article-title>Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study.</article-title>
              <source>Atherosclerosis</source>
              <year>2004</year>
              <volume>174</volume>
              <fpage>193</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
<italic toggle="yes">(5 patients with nonalcoholic steatohepatitis were treated with pravastatin [20 mg daily for 6 months], ALT levels became normal in all five patients and histology improved in some, but not fibrosis scores).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15135271</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.jacobson.2004.1140">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Jacobson</surname><given-names>TA</given-names></name>
</person-group>
              <article-title>Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.</article-title>
              <source>Am J Cardiol</source>
              <year>2004</year>
              <volume>94</volume>
              <fpage>1140</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Pharmacokinetic studies that demonstrate that drugs that inhibit CYP 3A4, the major P450 drug metabolizing enzyme [itraconazole, clarithromycin, verapamil], cause increases in blood levels of simvastatin and atorvastatin, but have little effect on pravastatin levels).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15518608</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.nissen.2005.61f">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Nissen</surname><given-names>SE</given-names></name>
</person-group>
              <article-title>Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.</article-title>
              <source>Am J Cardiol</source>
              <year>2005</year>
              <volume>96</volume>
              <issue>5A</issue>
              <fpage>61F</fpage>
              <lpage>68F</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Controlled trial comparing pravastatin [40 mg] to atorvastatin [80 mg] daily for 18 months in 654 patients; ALT elevations &#x0003e;3 times ULN occurred in 1.6% on pravastatin vs 2.3% on atorvastatin, but no instances of clinically apparent hepatitis).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15979434</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.andrade.2005.512">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Andrade</surname><given-names>RJ</given-names></name>
<name name-style="western"><surname>Lucena</surname><given-names>MI</given-names></name>
<name name-style="western"><surname>Fern&#x000e1;ndez</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Pelaez</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Pachkoria</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Garc&#x000ed;a-Ruiz</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Garc&#x000ed;a-Mu&#x000f1;oz</surname><given-names>B</given-names></name>
<etal/>
<collab>Spanish Group for the Study of Drug-Induced Liver Disease</collab>
</person-group>
              <article-title>Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.</article-title>
              <source>Gastroenterology</source>
              <year>2005</year>
              <volume>129</volume>
              <fpage>512</fpage>
              <lpage>21</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 461 cases of drug induced liver disease enrolled in a Spanish Registry between 1984 and 2004, 11 were attributed to statins, but no specific agent caused more than 4 cases).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">16083708</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.alsheikhali.2005.95">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Alsheikh-Ali</surname><given-names>AA</given-names></name>
<name name-style="western"><surname>Karas</surname><given-names>RH</given-names></name>
</person-group>
              <article-title>Adverse events with concomitant amiodarone and statin therapy.</article-title>
              <source>Prev Cardiol</source>
              <year>2005</year>
              <volume>8</volume>
              <fpage>95</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review of MedWatch adverse event reports for proportion that included combination with amiodarone; 1.0% for simvastatin, 0.7% atorvastatin and 0.4% pravastatin; 77% had muscle and 30% liver involvement).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15860984</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.conforti.2006.1163">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Conforti</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Magro</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Moretti</surname><given-names>U</given-names></name>
<name name-style="western"><surname>Scotto</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Motola</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Salvo</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Ros</surname><given-names>B</given-names></name>
<etal/>
</person-group>
              <article-title>Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.</article-title>
              <source>Drug Safety</source>
              <year>2006</year>
              <volume>29</volume>
              <fpage>1163</fpage>
              <lpage>72</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Italian Pharmacovigilance Group review of 35,757 adverse reaction reports: 1260 due to statins of which 178 were hepatic; 69 [36%] fluvastatin, 37 [21%] atorvastatin, 50 [28%] simvastatin, 16 [9%] pravastatin, 6 [3%] rosuvastatin; proportion reporting rate based on number of prescriptions was highest for fluvastatin [~9] compared to other agents [~2-3]; 26 fluvastatin cases described as &#x0201c;hepatitis&#x0201d;, but no details given except that most cases occurred within 90 days of starting).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">17147462</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.law.2006.52c">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Law</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Rudnicka</surname><given-names>AR</given-names></name>
</person-group>
              <article-title>Statin safety: a systematic review.</article-title>
              <source>Am J Cardiol</source>
              <year>2006</year>
              <volume>97</volume>
              <issue>8A</issue>
              <fpage>52C</fpage>
              <lpage>60C</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review of safety of statins; 38 cases of acute liver failure attributed to statins submitted to MedWatch by end of 1999, which gives an estimated rate of 1 per million person years of use; rate of confirmed ALT elevations &#x0003e;3 times ULN is 0.1% with statins and 0.04% with placebo).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">16581329</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.khorashadi.2006.902">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Khorashadi</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Hasson</surname><given-names>NK</given-names></name>
<name name-style="western"><surname>Cheung</surname><given-names>RC</given-names></name>
</person-group>
              <article-title>Incidence of statin hepatotoxicity in patients with hepatitis C.</article-title>
              <source>Clin Gastroenterol Hepatol</source>
              <year>2006</year>
              <volume>4</volume>
              <fpage>902</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Electronic record review of rate of ALT elevations in patients with hepatitis C with or without statin therapy and controls on statin therapy found no differences between the three groups [20%, 24% and 17%]; severe abnormalities most frequent in patients with chronic hepatitis C not on statin [6.6% vs 1.2%]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">16697272</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.silva.2006.26">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Silva</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Swanson</surname><given-names>AC</given-names></name>
<name name-style="western"><surname>Gandhi</surname><given-names>PJ</given-names></name>
<name name-style="western"><surname>Tataronis</surname><given-names>GR</given-names></name>
</person-group>
              <article-title>Statin-related adverse events: a meta-analysis.</article-title>
              <source>Clin Ther</source>
              <year>2006</year>
              <volume>28</volume>
              <fpage>26</fpage>
              <lpage>35</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Metaanalysis of adverse event rates in 18 placebo controlled trials of six statins in 71,108 patients; ALT elevations &#x0003e;3 times ULN in 1.7% of statin vs 1.4% placebo recipients; event rates highest with atorvastatin, lowest with fluvastatin).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">16490577</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.dale.2007.706">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Dale</surname><given-names>KM</given-names></name>
<name name-style="western"><surname>White</surname><given-names>CM</given-names></name>
<name name-style="western"><surname>Henyan</surname><given-names>NN</given-names></name>
<name name-style="western"><surname>Kluger</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Coleman</surname><given-names>CI</given-names></name>
</person-group>
              <article-title>Impact of statin dosing intensity on transaminase and creatine kinase.</article-title>
              <source>Am J Med</source>
              <year>2007</year>
              <volume>120</volume>
              <fpage>706</fpage>
              <lpage>12</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Metaanalysis of rates of ALT and CPK elevations in 9 controlled studies comparing low vs high doses of statins; ALT elevations &#x0003e;3 times ULN occurred in 1.5% of high- and 0.4% of low-intensity statin groups, effect particularly seen with hydrophilic [pravastatin and atorvastatin] compared to lipophilic agents [simvastatin and lovastatin]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">17679130</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.alsheikhali.2007.379">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Alsheikh-Ali</surname><given-names>AA</given-names></name>
<name name-style="western"><surname>Karas</surname><given-names>RH</given-names></name>
</person-group>
              <article-title>Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).</article-title>
              <source>Am J Cardiol</source>
              <year>2007</year>
              <volume>99</volume>
              <fpage>379</fpage>
              <lpage>81</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Analysis of MedWatch reports of adverse events found no excess in liver related adverse event reports per million prescription due to lovastatin alone [2.3] vs niacin alone [2.5] vs the combination [3.2], but slightly higher rates with atorvastatin [4.5], simvastatin [5.7] and pravastatin [4.9], but data relied upon spontaneous reporting).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">17261402</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.lewis.2007.1453">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Lewis</surname><given-names>JH</given-names></name>
<name name-style="western"><surname>Mortensen</surname><given-names>ME</given-names></name>
<name name-style="western"><surname>Zweig</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Fusco</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Medoff</surname><given-names>JR</given-names></name>
<name name-style="western"><surname>Belder</surname><given-names>R</given-names></name>
<collab>Pravastatin in Chronic Liver Disease Study Investigators</collab>
</person-group>
              <article-title>Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.</article-title>
              <source>Hepatology</source>
              <year>2007</year>
              <volume>46</volume>
              <fpage>1453</fpage>
              <lpage>63</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Controlled trial of pravastatin [80 mg daily] vs placebo for 36 weeks in 326 patients with chronic liver disease and hypercholesterolemia [64% nonalcoholic steatohepatitis and 25% chronic hepatitis C]; cumulative incidence of ALT levels &#x0003e;twice baseline or ULN was 7.5% for pravastatin and 12.5% for placebo, and none had exacerbation of underlying liver disease or jaundice).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">17668878</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.contreras.2007.70">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Contreras</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Monte&#x000f3;n</surname><given-names>FJ</given-names></name>
<name name-style="western"><surname>Flores</surname><given-names>MR</given-names></name>
<name name-style="western"><surname>Mendoza-S&#x000e1;nchez</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Ruiz</surname><given-names>I</given-names></name>
</person-group>
              <article-title>Drug-related hepatotoxicity in a renal transplant recipient with long-term survival and hepatitis C.</article-title>
              <source>Ann Hepatol</source>
              <year>2007</year>
              <volume>6</volume>
              <fpage>70</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
<italic toggle="yes">(26 year old man with a renal transplant had ALT elevations [peak 151 U/L] without jaundice after several years of pravastatin therapy, which did not improve with stopping pravastatin or azathioprine, and later found to be due to chronic hepatitis C).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">17297434</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.bhardwah.2007.597">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Bhardwah</surname><given-names>SS</given-names></name>
<name name-style="western"><surname>Chalasani</surname><given-names>N</given-names></name>
</person-group>
              <article-title>Lipid-lowering agents that cause drug-induced hepatotoxicity.</article-title>
              <source>Clin Liver Dis</source>
              <year>2007</year>
              <volume>11</volume>
              <fpage>597</fpage>
              <lpage>613</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review of hepatotoxicity of statins reported rates of ALT or AST elevations &#x0003e;3 times ULN: atorvastatin 0.7%, fluvastatin 1.2%, lovastatin 0.6%, pravastatin 1.4%, rosuvastatin 0% and simvastatin 1.8%. Abnormalities are usually asymptomatic, individual case reports of autoimmune hepatitis have been published).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">17723922</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.alsheikhali.2007.409">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Alsheikh-Ali</surname><given-names>AA</given-names></name>
<name name-style="western"><surname>Maddukuri</surname><given-names>PV</given-names></name>
<name name-style="western"><surname>Han</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Karas</surname><given-names>RH</given-names></name>
</person-group>
              <article-title>Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.</article-title>
              <source>J Am Coll Cardiol</source>
              <year>2007</year>
              <volume>50</volume>
              <fpage>409</fpage>
              <lpage>18</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Systematic review of relationship between LDL cholesterol lowering effects and adverse events in 23 statin treatment arms representing 309,506 person years of therapy; positive and graded relationship between statin dose [simvastatin, lovastatin and atorvastatin] and rates of ALT elevations, but no independent relationship to degree of LDL cholesterol decrease).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">17662392</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.chalasani.2008.1924">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Chalasani</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>RJ</given-names></name>
<name name-style="western"><surname>Bonkovsky</surname><given-names>HL</given-names></name>
<name name-style="western"><surname>Watkins</surname><given-names>PB</given-names></name>
<name name-style="western"><surname>Davern</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Serrano</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Rochon</surname><given-names>J</given-names></name>
<collab>Drug-Induced Liver Injury Network (DILIN)</collab>
</person-group>
              <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
              <source>Gastroenterology</source>
              <year>2008</year>
              <volume>135</volume>
              <fpage>1924</fpage>
              <lpage>34</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, 3 cases were attributed to atorvastatin, 3 to simvastatin/ezetimibe, and one each to pravastatin, fluvastatin, and simvastatin, but most cases were mild or not clearly attributable to the statin therapy).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">18955056</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.martin.2008.113">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Martin</surname><given-names>JE</given-names></name>
<name name-style="western"><surname>Cavanaugh</surname><given-names>TM</given-names></name>
<name name-style="western"><surname>Trumbull</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Bass</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Weber</surname><given-names>F</given-names><suffix>Jr</suffix></name>
<name name-style="western"><surname>Aranda-Michel</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Hanaway</surname><given-names>M</given-names></name>
<etal/>
</person-group>
              <article-title>Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients.</article-title>
              <source>Clin Transplant</source>
              <year>2008</year>
              <volume>22</volume>
              <fpage>113</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Retrospective review of adverse events associated with statin and fibrate use in 69 patients with liver transplants; myalgias problematic in 5, myopathy in 1, but none had significant ALT elevations or hepatitis related to medication).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">18217912</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.neuvonen.2008.463">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name>
<name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name>
<name name-style="western"><surname>Niemi</surname><given-names>M</given-names></name>
</person-group>
              <article-title>Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.</article-title>
              <source>Clin Pharmacokinet</source>
              <year>2008</year>
              <volume>47</volume>
              <fpage>463</fpage>
              <lpage>74</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review of literature on pharmacokinetics of statins; simvastatin and lovastatin are metabolized extensively by the P450 system and levels are affected by inhibitors or inducers of CYP 3A4 [itraconazole, erythromycin, verapamil, diltiazem, cyclosporine], whereas fluvastatin and pravastatin are minimally if at all affected).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">18563955</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.russo.2009.412">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Russo</surname><given-names>MW</given-names></name>
<name name-style="western"><surname>Scobey</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Bonkovsky</surname><given-names>HL</given-names></name>
</person-group>
              <article-title>Drug-induced liver injury associated with statins.</article-title>
              <source>Semin Liver Dis</source>
              <year>2009</year>
              <volume>29</volume>
              <fpage>412</fpage>
              <lpage>22</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Case reports and review of literature; 52 year old woman who developed fatigue 12 weeks after starting fluvastatin [bilirubin 1.2 mg/dL, ALT 850 U/L, Alk P 215 U/L, ANA negative], resolving on stopping fluvastatin, but recurring within 11 weeks of starting atorvastatin [bilirubin 1.0 rising to 12.5 mg/dL, ALT 1750 U/L, Alk P 285 U/L, ANA 1:160], responding to prednisone and azathioprine therapy).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">19826975</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.liu.2010.798">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Ding</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Fang</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Cheng</surname><given-names>KA</given-names></name>
<name name-style="western"><surname>Fang</surname><given-names>Q</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>GP</given-names></name>
</person-group>
              <article-title>Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin.</article-title>
              <source>Int J Clin Pharmacol Ther</source>
              <year>2010</year>
              <volume>48</volume>
              <fpage>798</fpage>
              <lpage>802</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Two men, ages 53 and 58, developed ALT elevations [peak 120 and 278 U/L] within a day of starting atorvastatin, resolving within 7 days of stopping and not recurring in either when pravastatin was started).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">21084035</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.hippisleycox.2010.c2197">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Hippisley-Cox</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Coupland</surname><given-names>C</given-names></name>
</person-group>
              <article-title>Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database.</article-title>
              <source>BMJ</source>
              <year>2010</year>
              <volume>340</volume>
              <fpage>c2197</fpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 225,922 new users of statins in a UK health care database, there was an increased risk of moderate or severe liver dysfunction [ALT &#x0003e;3 times ULN], usually within first 6 months and associated with higher doses of statins; relative risks were highest with fluvastatin [2.53 in women, 1.97 in men] and lowest with pravastatin [0.93 to 1.58]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">20488911</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.reuben.2010.2065">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Reuben</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Koch</surname><given-names>DG</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>WM</given-names></name>
<collab>Acute Liver Failure Study Group</collab>
</person-group>
              <article-title>Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.</article-title>
              <source>Hepatology</source>
              <year>2010</year>
              <volume>52</volume>
              <fpage>2065</fpage>
              <lpage>76</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury including 2 due to atorvastatin, 2 simvastatin and 2 cerivastatin, but none to pravastatin).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">20949552</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.bj_rnsson.2012.374">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Bj&#x000f6;rnsson</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Jacobsen</surname><given-names>EI</given-names></name>
<name name-style="western"><surname>Kalaitzakis</surname><given-names>E</given-names></name>
</person-group>
              <article-title>Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing.</article-title>
              <source>J Hepatol</source>
              <year>2012</year>
              <volume>56</volume>
              <fpage>374</fpage>
              <lpage>80</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Between 1988 and 2010, the Swedish registry received 217 adverse event reports possibly related to statins, 124 [57%] being liver related, 73 of which could be evaluated: 2 were fatal and one led to liver transplant; 3 had positive rechallenge; 43 [59%] were hepatocellular, 22 [30%] cholestatic and 8 [11%] mixed; 30 were due to atorvastatin, 28 simvastatin, 11 fluvastatin, 2 pravastatin and 2 rosuvastatin, arising after 30-248 days; atorvastatin injury was more likely to be cholestatic and was estimated to occur in 2.9 per 100,000 person years).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">21889469</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.farnier.2012.281">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Farnier</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Marcereuil</surname><given-names>D</given-names></name>
<name name-style="western"><surname>De Niet</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Ducobu</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Steinmetz</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Retterst&#x000f8;l</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Bryniarski</surname><given-names>L</given-names></name>
<etal/>
</person-group>
              <article-title>Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.</article-title>
              <source>Clin Drug Investig</source>
              <year>2012</year>
              <volume>32</volume>
              <fpage>281</fpage>
              <lpage>91</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Analysis of fixed combination of pravastatin with fenofibrate vs each alone in 5 large trials found no case of drug induced liver injury or rhabdomyolysis; elevations in ALT &#x0003e;3 times ULN occurred in 1.6% [2/122] on fenofibrate, 0.2% [1/519] on statins and 1.0% [16/1566] on the fixed combination, but all were transient and not accompanied by jaundice).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">22350498</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.sirtori.2012.419">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Sirtori</surname><given-names>CR</given-names></name>
<name name-style="western"><surname>Mombelli</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Triolo</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Laaksonen</surname><given-names>R</given-names></name>
</person-group>
              <article-title>Clinical response to statins: mechanism(s) of variable activity and adverse effects.</article-title>
              <source>Ann Med</source>
              <year>2012</year>
              <volume>44</volume>
              <fpage>419</fpage>
              <lpage>32</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review of the possible mechanisms for the beneficial and adverse effects of statins, including genetic variations in CYP enzymes, ABC transporters and HLA genes in causing adverse events, focused mostly upon myopathy and myalgias).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">21623698</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.bj_rnsson.2013.1419">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Bj&#x000f6;rnsson</surname><given-names>ES</given-names></name>
<name name-style="western"><surname>Bergmann</surname><given-names>OM</given-names></name>
<name name-style="western"><surname>Bj&#x000f6;rnsson</surname><given-names>HK</given-names></name>
<name name-style="western"><surname>Kvaran</surname><given-names>RB</given-names></name>
<name name-style="western"><surname>Olafsson</surname><given-names>S</given-names></name>
</person-group>
              <article-title>Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland.</article-title>
              <source>Gastroenterology</source>
              <year>2013</year>
              <volume>144</volume>
              <fpage>1419</fpage>
              <lpage>25</lpage>
              <annotation>
                <p>
<italic toggle="yes">(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, including 2 attributed to atorvastatin and 1 to simvastatin, but none to pravastatin).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">23419359</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Hern&#x000e1;ndez</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Bessone</surname><given-names>F</given-names></name>
<name name-style="western"><surname>S&#x000e1;nchez</surname><given-names>A</given-names></name>
<name name-style="western"><surname>di Pace</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Brahm</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Zapata</surname><given-names>R, A</given-names></name>
<name name-style="western"><surname>Chirino</surname><given-names>R</given-names></name>
<etal/>
</person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, none of which were attributed to statins or lipid lowering agents).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.russo.2014.679">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Russo</surname><given-names>MW</given-names></name>
<name name-style="western"><surname>Hoofnagle</surname><given-names>JH</given-names></name>
<name name-style="western"><surname>Gu</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>RJ</given-names></name>
<name name-style="western"><surname>Barnhart</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Kleiner</surname><given-names>DE</given-names></name>
<name name-style="western"><surname>Chalasani</surname><given-names>N</given-names></name>
<etal/>
</person-group>
              <article-title>Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network.</article-title>
              <source>Hepatology</source>
              <year>2014</year>
              <volume>60</volume>
              <fpage>679</fpage>
              <lpage>86</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 1,188 cases of drug induced liver disease collected in the US between 2004 to 2012, 22 [2%] were attributed to statins, including atorvastatin [8], simvastatin [5], rosuvastatin [4], fluvastatin [2], pravastatin [2] and lovastatin [1]; median age was 60 years and 68% were women; 9 cases were cholestatic and 12 hepatocellular [6 with autoimmune features]; the latency ranged widely, from 1 month to 10 years; only one case was fatal [a man with preexisting cirrhosis presenting with acute-on-chronic liver failure]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">24700436</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.bays.2014.s47">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Bays</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Cohen</surname><given-names>DE</given-names></name>
<name name-style="western"><surname>Chalasani</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Harrison</surname><given-names>SA</given-names></name>
</person-group>
              <article-title>An assessment by the Statin Liver Safety Task Force: 2014 update.</article-title>
              <source>J Clin Lipidol</source>
              <year>2014</year>
              <volume>8</volume>
              <issue>3</issue>
              <supplement>Suppl</supplement>
              <fpage>S47</fpage>
              <lpage>57</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review of the safety of statins including their use in patients with liver disease recommending that liver tests be obtained before therapy, but that routine monitoring is not necessary and that statins can be safety used in patients with nonalcoholic liver disease, and are probably safe in other forms of chronic liver disease and after liver transplantation).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">24793441</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.ooba.2014.e96919">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Ooba</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Sato</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Wakana</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Orii</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Kitamura</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Kokan</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Kurata</surname><given-names>H</given-names></name>
<etal/>
</person-group>
              <article-title>A prospective stratified case-cohort study on statins and multiple adverse events in Japan.</article-title>
              <source>PLoS One</source>
              <year>2014</year>
              <volume>9</volume>
              <elocation-id>e96919</elocation-id>
              <annotation>
                <p>
<italic toggle="yes">(Among 6877 patients started on statins between 2008 and 2010, 139 developed an increase in ALT or AST deemed likely due to the drug with no significant differences among those treated with pra-, ator-, flu-, pita- or rosu-vastatin).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">24810427</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.macedo.2014.51">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Macedo</surname><given-names>AF</given-names></name>
<name name-style="western"><surname>Taylor</surname><given-names>FC</given-names></name>
<name name-style="western"><surname>Casas</surname><given-names>JP</given-names></name>
<name name-style="western"><surname>Adler</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Prieto-Merino</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Ebrahim</surname><given-names>S</given-names></name>
</person-group>
              <article-title>Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis.</article-title>
              <source>BMC Med</source>
              <year>2014</year>
              <volume>12</volume>
              <fpage>51</fpage>
              <annotation>
                <p>
<italic toggle="yes">(Systematic review of 90 studies of 48 different "unintended effects" of statins with evidence of an increased risk of myopathy [Odds Ratio: OR=2.6] and raised liver enzymes [OR=1.5]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">24655568</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF48">
            <element-citation publication-type="journal">
              <article-title>Drugs for lipids.</article-title>
              <source>Treat Guidel Med Lett</source>
              <year>2014</year>
              <volume>12</volume>
              <issue>137</issue>
              <fpage>1</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Concise recommendations on management of hyperlipidemia mentions that 1-2% of patients on high doses of statins develop ALT elevations [above 3 times ULN], but that there is not always cross sensitivity to this side effect and that patients with mild-to-moderate ALT elevations can tolerate statins; no discussion of clinically apparent liver).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">24419209</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.perdices.2014.246">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Perdices</surname><given-names>EV</given-names></name>
<name name-style="western"><surname>Medina-C&#x000e1;liz</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Hernando</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Ortega</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Mart&#x000ed;n-Oca&#x000f1;a</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Navarro</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Pel&#x000e1;ez</surname><given-names>G</given-names></name>
<etal/>
</person-group>
              <article-title>Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry.</article-title>
              <source>Rev Esp Enferm Dig</source>
              <year>2014</year>
              <volume>106</volume>
              <fpage>246</fpage>
              <lpage>54</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 858 cases of drug induced liver injury enrolled in a Spanish Registry between 1994 and 2012, 47 [5.5%] were attributed to statins [16 atorvastatin, 13 simvastatin, 12 fluvastatin, 4 lovastatin and 2 pravastatin], usually with a hepatocellular pattern of injury, 8.5% with autoimmune features, chronic injury in 19%, and no liver related deaths).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">25075655</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.chen.2014.719">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Chen</surname><given-names>GL</given-names></name>
<name name-style="western"><surname>Hsiao</surname><given-names>FY</given-names></name>
<name name-style="western"><surname>Dong</surname><given-names>YH</given-names></name>
<name name-style="western"><surname>Shen</surname><given-names>LJ</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>FL</given-names></name>
</person-group>
              <article-title>Statins and the risk of liver injury: a population-based case-control study.</article-title>
              <source>Pharmacoepidemiol Drug Saf</source>
              <year>2014</year>
              <volume>23</volume>
              <fpage>719</fpage>
              <lpage>25</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 2165 Taiwanese patients hospitalized for liver injury between 2002 and 2009, use of statins was not more frequent than among 16,600 hospitalized controls, except for use of high doses of rosuvastatin [adjusted odds ratio of 2.29]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">24829162</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Chalasani</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Bonkovsky</surname><given-names>HL</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Stolz</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Talwalkar</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Reddy</surname><given-names>KR</given-names></name>
<etal/>
<collab>United States Drug Induced Liver Injury Network</collab>
</person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 31 cases [3.4%] were attributed to statins, including 8 to atorvastatin, 8 simvastatin, 7 rosuvastatin, 4 pravastatin, 2 fluvastatin and 2 lovastatin).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.carrascosa.2015.751">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Carrascosa</surname><given-names>MF</given-names></name>
<name name-style="western"><surname>Salcines-Caviedes</surname><given-names>JR</given-names></name>
<name name-style="western"><surname>Lucena</surname><given-names>MI</given-names></name>
<name name-style="western"><surname>Andrade</surname><given-names>RJ</given-names></name>
</person-group>
              <article-title>Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity?</article-title>
              <source>J Hepatol</source>
              <year>2015</year>
              <volume>62</volume>
              <fpage>751</fpage>
              <lpage>2</lpage>
              <annotation>
                <p>
<italic toggle="yes">(85 year old woman on atorvastatin for more than a year developed jaundice after increasing dose from 40 to 80 mg daily [bilirubin 4.1 mg/dL, ALT 909 U/L, Alk P 415 U/L, CK 4753 U/L, INR 1.71], with transient worsening, but ultimate improvement and resolution).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">25463547</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.chang.2015.155">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Chang</surname><given-names>CH</given-names></name>
<name name-style="western"><surname>Chang</surname><given-names>YC</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>YC</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>YC</given-names></name>
<name name-style="western"><surname>Chuang</surname><given-names>LM</given-names></name>
<name name-style="western"><surname>Lin</surname><given-names>JW</given-names></name>
</person-group>
              <article-title>Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study.</article-title>
              <source>J Gastroenterol Hepatol</source>
              <year>2015</year>
              <volume>30</volume>
              <fpage>155</fpage>
              <lpage>62</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 37,929 Taiwanese persons with chronic liver disease started on statin therapy for hyperlipidemia between 2005 and 2009, there were 912 incident cases of hospitalization for liver injury, rates being similar for the 6 different statins used [1.94-2.95 per 100,000 person-days], but higher in those on high doses of atorvastatin [40 or 80 mg daily]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">25041076</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.kim.2016.266">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Kim</surname><given-names>HS</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name>
<name name-style="western"><surname>Cho</surname><given-names>JH</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Yim</surname><given-names>HW</given-names></name>
<etal/>
</person-group>
              <article-title>Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea.</article-title>
              <source>J Clin Pharm Ther</source>
              <year>2016</year>
              <volume>41</volume>
              <fpage>266</fpage>
              <lpage>72</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 21,233 Korean patients starting statin therapy between 2009 and 2013, abnormal ALT or AST values above 3 times ULN were more frequent among those with mild baseline elevations).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">27015878</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.bj_rnsson.2017.173">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Bj&#x000f6;rnsson</surname><given-names>ES</given-names></name>
</person-group>
              <article-title>Hepatotoxicity of statins and other lipid-lowering agents.</article-title>
              <source>Liver Int</source>
              <year>2017</year>
              <volume>37</volume>
              <fpage>173</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review of the hepatotoxicity of statins mentions that atorvastatin has been the most frequently implicated statin [accounting for 30-40% of cases] in drug induced liver injury estimated to arise in 1 in 17,000 users, cholestatic in 56% and with autoimmune features in 10% and rarely fatal).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">27860156</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.wang.2016.823">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Wang</surname><given-names>LY</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>YS</given-names></name>
<name name-style="western"><surname>Perng</surname><given-names>CL</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Lin</surname><given-names>HC</given-names></name>
</person-group>
              <article-title>Statin-induced liver injury in an area endemic for hepatitis B virus infection: risk factors and outcome analysis.</article-title>
              <source>Br J Clin Pharmacol</source>
              <year>2016</year>
              <volume>82</volume>
              <fpage>823</fpage>
              <lpage>30</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Analysis of the Taipei Veterans Hospital database from 2008 to 2012 identified 108 patients with statin-associated liver injury [including 28 rosu-, 20 flu-, 17 sim-, 11 pra-, 8 lo-, and 8 pita-vastatin] most of which 75 [69%] were mild and only one fatal [80 year old on rosuvastatin], and there were no differences in disease features or peak enzyme or bilirubin levels between HBsAg positive vs negative subjects [n=16 vs 92]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">27197051</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.giugliano.2017.547">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Giugliano</surname><given-names>RP</given-names></name>
<name name-style="western"><surname>Wiviott</surname><given-names>SD</given-names></name>
<name name-style="western"><surname>Blazing</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>De Ferrari</surname><given-names>GM</given-names></name>
<name name-style="western"><surname>Park</surname><given-names>JG</given-names></name>
<name name-style="western"><surname>Murphy</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>White</surname><given-names>JA</given-names></name>
<etal/>
</person-group>
              <article-title>Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT Trial.</article-title>
              <source>JAMA Cardiol.</source>
              <year>2017</year>
              <volume>2</volume>
              <fpage>547</fpage>
              <lpage>555</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 15,281 patients recovering from an acute cardiac syndrome treated with simvastatin [40 mg daily] with or without ezetimibe for up to 6 years, 6.4% achieved very low LDL-cholesterol levels [&#x0003c;30 mg/dL] and subsequently had low rates of cardiovascular events, but also no increase in rates of adverse events from statins such including ALT elevations above 3 times ULN [2.2% vs 1.8-2.1%]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">28291866</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.liang.2018.7092414">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Liang</surname><given-names>X</given-names></name>
<name name-style="western"><surname>He</surname><given-names>Q</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></name>
</person-group>
              <article-title>Effect of stains on LDL reduction and liver safety: a systematic review and meta-analysis.</article-title>
              <source>Biomed Res Int.</source>
              <year>2018</year>
              <volume>2018</volume>
              <elocation-id>7092414</elocation-id>
              <annotation>
                <p>
<italic toggle="yes">(In a systematic review of 16 controlled trials of statins in 74,078 patients, rates of liver test abnormalities were higher with statin therapy [odds ratio, OR=1.18] but this was significant only for fluvastatin [OR=3.5] and with higher doses [40-80 mg daily] [OD=3.6] and was not significant for statins used at low or moderate doses).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">29693013</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.yebyo.2019.18">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Yebyo</surname><given-names>HG</given-names></name>
<name name-style="western"><surname>Aschmann</surname><given-names>HE</given-names></name>
<name name-style="western"><surname>Kaufmann</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Puhan</surname><given-names>MA</given-names></name>
</person-group>
              <article-title>Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.</article-title>
              <source>Am Heart J.</source>
              <year>2019</year>
              <volume>210</volume>
              <fpage>18</fpage>
              <lpage>28</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Metaanalyses of 40 trials of statins that enrolled 94,283 patients followed for a median of 1 year for efficacy and safety reported that statins as a class increased the risk of hepatic dysfunction by 6% with fluvastatin having the highest relative risk).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">30716508</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF60">
            <element-citation publication-type="journal">
              <article-title>Lipid-lowering drugs.</article-title>
              <source>Med Lett Drugs Ther.</source>
              <year>2019</year>
              <volume>61</volume>
              <issue>1565</issue>
              <fpage>17</fpage>
              <lpage>24</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Concise review of the mechanism of action, relative efficacy, safety and costs of lipid lowering drugs including statins, ezetimibe, PCSK9 inhibitors, bile acid sequestrants, fibric acid derivatives niacin and fish oil, mentions that statin therapy is associated with ALT elevations above 3 times ULN in 1-3% of patients but &#x0201c;whether statins actually cause liver damage is unclear&#x0201d;).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">30845106</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.simon.2020.3">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Simon</surname><given-names>TG</given-names></name>
</person-group>
              <article-title>When less is more: dosing simvastatin in decompensated cirrhosis.</article-title>
              <source>Lancet Gastroenterol Hepatol.</source>
              <year>2020</year>
              <volume>5</volume>
              <fpage>3</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Editorial in response to Pose et al [2020] discusses the possible beneficial effects of statins in patients with cirrhosis and the issue of increased rate of muscle toxicity with 40 vs to 20 mg daily).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">31607676</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.hopewell.2020.3336">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Hopewell</surname><given-names>JC</given-names></name>
<name name-style="western"><surname>Offer</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Haynes</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Bowman</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Bulbulia</surname><given-names>R</given-names></name>
<etal/>
</person-group>
              <article-title>Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom.</article-title>
              <source>Eur Heart J</source>
              <year>2020</year>
              <volume>41</volume>
              <fpage>3336</fpage>
              <lpage>3342</lpage>
              <annotation>
                <p>
<italic toggle="yes">(In a combined analysis of 3 large clinical trials in patients with cardiovascular disease treated with simvastatin for a mean of 3.4 years, 171 of 58,390 participants [0.1%] developed myopathy [muscle pain and CK levels above 10 times ULN], and risk was higher with higher doses, in Asian subjects, women, and persons with higher BMI and multiple comorbidities as well as with SLCO1B1 genotype).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">32702748</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.balasubramanian.2021.328">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Balasubramanian</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Maideen</surname><given-names>NMP</given-names></name>
</person-group>
              <article-title>HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview.</article-title>
              <source>Curr Drug Metab.</source>
              <year>2021</year>
              <volume>22</volume>
              <fpage>328</fpage>
              <lpage>341</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Systematic review of literature on drug-drug interactions with statins and their clinical significance mentions that toxicity can be enhanced by inhibitors of CYP3A4 [ator-, sim- and lo-vastatin] as well as by inhibitors of P glycoprotein and OATP1B1 [most statins including rosuvastatin] with specific recommendations for the most common inhibitors).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">33459228</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.sung.2021.120">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Sung</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Al-Karaghouli</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Kalainy</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Cabrera Garcia</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Abraldes</surname><given-names>JG</given-names></name>
</person-group>
              <article-title>A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis.</article-title>
              <source>BMC Gastroenterol.</source>
              <year>2021</year>
              <volume>21</volume>
              <fpage>120</fpage>
              <annotation>
                <p>
<italic toggle="yes">(Systematic review of literature suggests that rosuvastatin and pitavastatin pharmacokinetics are unchanged in patients with Child&#x02019;s Class A cirrhosis as opposed to atorvastatin and pravastatin, although unlike rosuvastatin, simvastatin, atorvastatin and pravastatin have been assessed in clinical trials in cirrhotic patients).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">33726685</pub-id>
            </element-citation>
          </ref>
          <ref id="Pravastatin.REF.cai.2021">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Cai</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Abel</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Langford</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Monaghan</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Aronson</surname><given-names>JK</given-names></name>
<name name-style="western"><surname>Stevens</surname><given-names>RJ</given-names></name>
<name name-style="western"><surname>Lay-Flurrie</surname><given-names>S</given-names></name>
<etal/>
</person-group>
              <article-title>Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses.</article-title>
              <source>BMJ</source>
              <year>2021</year>
              <volume>374</volume>
              <issue>n1537</issue>
              <annotation>
                <p>
<italic toggle="yes">(Systematic review of placebo controlled trials of statins for cardiovascular disease prevention identified 62 publications with 120,456 patients and found an increased risk of muscle symptoms, liver test abnormalities, renal insufficiency and eye conditions for all 7 statins, but not muscle disorders or diabetes; rosuvastatin having relatively high risk for muscle symptoms and renal abnormalities and also was also associated with eye conditions and diabetes while atorvastatin and lovastatin had highest risk for liver abnormalities).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">34261627</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Pravastatin.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=pravastatin+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Pravastatin: from PubMed.gov</ext-link>
</p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=pravastatin">Trials on Pravastatin: from ClinicalTrials.gov</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
